RXiBreeze PAP System (RXiBreeze 20C)— 510(k) K253044
Substantially EquivalentResvent Medical Technology Co., Ltd.
FDA 510(k) clearance K253044 for RXiBreeze PAP System (RXiBreeze 20C), Substantially Equivalent on 2026-07-23. Applicant: Resvent Medical Technology Co., Ltd.. Device class: 2.
Summary
Resvent Medical Technology's RXiBreeze PAP System (RXiBreeze 20C) is filed under BZD, non-continuous ventilators (respirators). The record doesn't expand "PAP" or give specs.
Class II, 21 CFR 868.5905. Anesthesiology is both the classification panel and the review panel. It came in as a Traditional 510(k).
Resvent filed from Shenzhen, China. The decision came 304 calendar days after FDA received it (September 22, 2025 to July 23, 2026).
Clearance details
- Applicant
- Resvent Medical Technology Co., Ltd.
- Product code
- Product code BZD
- Device class
- Class 2
- Regulation
- 21 CFR 868.5905
- Advisory panel
- Anesthesiology
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Traditional
- Location
- Shenzhen, CN
Recent devices under product code BZD
view allAdverse events under product code BZD
product code BZD- Death
- 4,440
- Injury
- 53,099
- Malfunction
- 213,222
- Other
- 17
- Total
- 270,778
Source: openFDA MAUDE database, through . Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →
Data sourced from openFDA. This site is unofficial and independent of the FDA.